Drug Insight: thalidomide as a treatment for multiple myeloma
- 1 May 2005
- journal article
- review article
- Published by Springer Nature in Nature Clinical Practice Oncology
- Vol. 2 (5), 262-270
- https://doi.org/10.1038/ncponc0174
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implicationsBlood, 2005
- Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansionBlood, 2004
- Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progressionBlood, 2004
- Advances in biology of multiple myeloma: clinical applicationsBlood, 2004
- Pathogenesis of myeloma bone diseaseBlood Cells, Molecules, and Diseases, 2004
- Effect of thalidomide therapy on bone marrow angiogenesis in multiple myelomaLeukemia, 2004
- Moving disease biology from the lab to the clinicCancer, 2003
- Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myelomaBlood, 2002
- Pharmacokinetics and Pharmacodynamics of Thalidomide in HIV Patients Treated for Oral Aphthous Ulcers: ACTG Protocol 251The Journal of Clinical Pharmacology, 2001
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999